Results 161 to 170 of about 143,744 (251)

Variations in Treatment Prescription and Survival Outcomes Between Older and Younger Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Radiotherapy

Head &Neck, EarlyView.
ABSTRACT Purpose To investigate treatment variations and outcomes between older (≥ 70 years) and younger (< 70 years) patients with mucosal head and neck squamous cell carcinoma (mHNSCC) treated with radiotherapy. Methods A multicenter retrospective review of patients diagnosed from 2010 to 2018 was conducted.
Farhannah Aly, Joseph Descallar, Purnima Sundaresan, Alexis Andrew Miller, Lois Holloway, Shalini Vinod   +5 more
wiley   +1 more source

Multi-omics analysis reveals key genes associated with clear cell renal cell carcinoma. [PDF]

PeerJ
Chen X, Han T, Zhan M, Zhang X, Wang W, Wu K.   +5 more
europepmc   +1 more source

Nectin-4 expression in clear cell renal cell carcinoma

Scientific Reports
Kyra Klein, Steffen Rausch, Veronika Bahlinger, Moritz Maas, Simon Walz, Igor Tsaur, Viktoria Stühler   +6 more
doaj   +1 more source

From Genes to Proteins: The Indispensable Role of Proteogenomics in Advancing Clear Cell Renal Cell Carcinoma Research. [PDF]

Int J Mol Sci
Kasperczak F, Pawłowska-Kasperczak K, Szuścik A, Zysnarska M, Rajwa P, Yanagisawa T, Zattoni F, Kasperczak M.   +7 more
europepmc   +1 more source

Wunderlich Syndrome in a Patient With Coexisting Giant Angiomyolipoma and Multicystic Clear Cell Renal Cell Carcinoma: A Case Report. [PDF]

Cureus
Gupta R, Rathi P, Bansal N, Koli J.
europepmc   +1 more source

Mechanistic study of MUC3A in promoting progression of clear cell renal cell carcinoma via the JAK‑STAT pathway. [PDF]

Oncol Rep
Yun Y, Ji X, Hu S, Wu T, Liu Y, Li Z, Sun Z, Zhou P, Yang L, Yu W.   +9 more
europepmc   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, EarlyView.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source

Complete response in metastatic clear cell renal cell carcinoma following pembrolizumab-axitinib and subsequent nephrectomy: a Case Report. [PDF]

Front Immunol
Polito MG, Caruso D, Cosimati A, Ramirez Reinaga CA, Leka E, Fuschi A, Pastore AL, Carbone A, Lako K, Di Cristofano C, Petrozza V, Santini D, Spinelli GP.   +12 more
europepmc   +1 more source

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle‐Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab‐Gemcitabine‐Cisplatin Versus Gemcitabine‐Cisplatin: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials

International Journal of Cancer, EarlyView.
Optimizing neoadjuvant therapy for muscle‐invasive bladder cancer patients who are eligible for cisplatin remains difficult, owing particularly to high toxicity and recurrence rates. This meta‐analysis compared dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) against durvalumab plus gemcitabine‐cisplatin (D‐GC) and GC alone ...
Maurin Helen Mangold, Gloria Baumann, Victoria Luise Simone Wieland, Nicolas Carl, Luisa Vivienne Renner, Alexander Studier‐Fischer, Hanna Menold, Stefanie Zschäbitz, Frederik Wessels, Niklas Westhoff, Maurice Stephan Michel, Karl‐Friedrich Kowalewski, Caelán Max Haney‐Aubert   +12 more
wiley   +1 more source

Deep-learning-based artificial intelligence approaches for grading and progression prediction of clear cell renal cell carcinoma. [PDF]

iScience
Zhou J, Su B, Zhao C, Huang Q, Cheng N, Di J, Gu J, Liu H, Liang Q, Hui D, Weng Z, Tang L, Yang R, Han L, Chen J, Ren Y, Shao C.   +16 more
europepmc   +1 more source